TX-MARY-KAY-INC
Mary Kay Inc., a global leader in women’s empowerment and staunch advocate for sustainability, is once again at the forefront of global ocean conservation efforts. The beauty brand was proud to participate at the 11th Annual World Ocean Summit & Expo, held in Lisbon, Portugal, from March 11-13. As a bronze level sponsor for the second consecutive year, Mary Kay demonstrated its unwavering commitment to fostering a sustainable blue economy as a private sector representative and through its long-standing collaboration with The Nature Conservancy (TNC).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240403166440/en/
Sandra Silva, General Manager of Mary Kay in Portugal, shared insights on the crucial need for collaborative efforts in marine conservation and highlighted the impact of incorporating gender perspectives in initiatives tackling climate change challenges and biodiversity loss. (Photo: Mary Kay Inc.)
The Annual World Ocean Summit & Expo, organized by Economist Impact, convened over 200 expert speakers and a diverse international audience to engage in meaningful discussions, workshops, and "How to" sessions. These gatherings focused on actionable solutions to some of the most pressing oceanic challenges, underlining the importance of collaborative efforts across sectors.
Sandra Silva, General Manager of Mary Kay Portugal, took an active role in the panel discussion titled "Developing Blue Nature-based Projects." Silva shared insights on the crucial need for collaborative efforts in marine conservation and highlighted the impact of incorporating gender perspectives in initiatives tackling climate change challenges and biodiversity loss.
"Mary Kay's participation at this year's World Ocean Summit was not only about reinforcing our dedication to ocean conservation, but also about spotlighting the essential role of women in these efforts,” said Silva. “We believe that our collective actions today are pivotal for the preservation of marine ecosystems. All stakeholders left the summit with a clear vision on new synergies, a focus on actionable strategies, and soundproof solutions to enhance ocean stewardship.”
Dr. Lizzie Mcleod, Global Ocean Director for The Nature Conservancy, expressed gratitude for their long-term and impactful relationship with Mary Kay. "Our strong collaboration stands as a testament to the power of joining forces across the scientific community and the private sector to improve ocean health. Mary Kay’s support of marine conservation initiatives, including the Super Reefs project in Palau, is one example of our collective effort to ensure a healthy and resilient ocean."
Mary Kay has been working to elevate ocean health and coral reef awareness through its support of The Nature Conservancy for 37 years. Some of the most recent projects include the Super Reef restoration in the Asia Pacific region and other projects in Hawaii, Palau, the Marshall Islands, and Belize. These projects align with Mary Kay's mission to not only enrich lives but also to ensure the longevity and health of marine environments for future generations.
DID YOU KNOW?
- Mary Kay began supporting The Nature Conservancy (TNC) in 1987 and has now contributed to projects for more than three decades across 100 conservation projects around the globe.
- As part of its mission to conserve the Earth’s land and water, TNC aims to conserve 4 billion hectares of ocean by 2030—including coral reefs.
- Out of more than 1,500 articles published on coral reef sciences in OECD countries, 33% of authors were women.1
- 13-24% of senior positions in the EU’s marine sciences sector are occupied by women.1
- 90% of women in fisheries and aquaculture are more involved in less well-paid or unpaid work.1
About Mary Kay
Then. Now. Always. One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty brand in Texas in 1963 with one goal: to enrich women’s lives. That dream has blossomed into a global company with millions of independent sales force members in more than 35 countries. For 60 years, the Mary Kay opportunity has empowered women to define their own futures through education, mentorship, advocacy, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in preserving our planet for future generations, protecting women impacted by cancer and domestic abuse, and encouraging youth to follow their dreams. Learn more at marykayglobal.com, find us on Facebook, Instagram, and LinkedIn, or follow us on X (formerly Twitter).
About The Nature Conservancy
The Nature Conservancy is a global conservation organization dedicated to conserving the lands and waters on which all life depends. Guided by science, we create innovative, on-the-ground solutions to our world’s toughest challenges so that nature and people can thrive together. We are tackling climate change, conserving lands, waters, and oceans at an unprecedented scale, providing food and water sustainably, and helping make cities more sustainable. Working in 76 countries and territories —37 by direct conservation impact and 39 through partners— we use a collaborative approach that engages local communities, governments, the private sector, and other partners. To learn more, visit www.nature.org or follow @nature_press on Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240403166440/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
Illumynt Reports Q3 2025 Business Update17.10.2025 14:39:00 CEST | Press release
Q3 2025 was a busy quarter once again for us here at illumynt. In addition to naming a new CEO, we executed on a number of initiatives that are propelling our organization forward. Revenue for the quarter exceeded $30 million- keeping us on track for our 2025 plan. More importantly we executed three different large-scale data center decommission projects with almost no material ending up as scrap. All of the AI-focused enterprise equipment and components recovered from the decommissions were resold at top market value. We head into Q4 with high expectations and our eyes wide open. We’re celebrating the 20-year anniversary of our facility in Hong Kong and looking to add another location in the region to help us process inbound AI data center equipment. Stay tuned for updates. There will be more on the way. View source version on businesswire.com: https://www.businesswire.com/news/home/20251017446548/en/
Avanzanite Bioscience’s Partner Agios Announces Positive CHMP Opinion for PYRUKYND® (mitapivat) for Adults with Thalassemia17.10.2025 14:15:00 CEST | Press release
Avanzanite entered an exclusive partnership with Agios in June 2025 to manage PYRUKYND commercialization across Europe European Commission will now review the CHMP’s opinion, with the final decision expected by early 2026 PYRUKYND is currently approved in Europe for adults with PK deficiency; thalassemia would represent its second indication, pending European Commission approval Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the new indication for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for t
Kinaxis Accelerates Agentic Era for Supply Chain Orchestration with the Launch of Maestro Agents17.10.2025 13:00:00 CEST | Press release
AI agents that plan with you, not just for you, empower the customer journey to a next generation of the adaptive supply chain Kinaxis® Inc. (TSX: KXS), a global leader in supply chain orchestration, today announced Maestro Agents, marking the next milestone in AI-enabled decision intelligence for supply chains. Now available to Kinaxis customers and embedded natively in Kinaxis Maestro®, these AI-powered context aware digital co-workers help planners move faster from issue to action, turning disruption into opportunity, and strengthening the resilience of the supply chains that power the global economy. “Kinaxis agents are already helping our planning team collaborate more effectively with customers and contract manufacturers,” said John Finnigan, Senior Director, Advanced Planning at Jabil. “With human-in-the-loop safeguards, we’re reaching decisions faster today and see strong potential to build a more resilient and networked supply chain.” Maestro Agents advance the customer journe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom